切换至 "中华医学电子期刊资源库"
高级检索
中华普通外科学文献(电子版)

中华普通外科学文献(电子版) ›› 2017, Vol. 11 ›› Issue (01) : 9 -12. doi: 10.3877/cma.j.issn.1674-0793.2017.01.003

所属专题： 文献；

论著

高尔基糖蛋白73在早期原发性肝癌中的表达及意义
张金玲1, 吴超2, 赵志辉3,†()   
  1. 1. 276600　山东省临沂市莒南县人民医院消化内科
    2. 276600　山东省临沂市莒南县人民医院普外科
    3. 430007　武汉，华中科技大学同济医学院附属梨园医院普外科
  • 收稿日期:2016-10-24 出版日期:2017-02-01
  • 通信作者: 赵志辉
  • 基金资助:
    湖北省卫生厅科研项目(JX6B54)

Expression and significance of Golgi glycoprotein-73 in early hepatocellular carcinoma

Jinling1 Zhang1, Chao Wu2, Zhihui Zhao3,†()   

  1. 1. Department of Gastroenterology, People's Hospital of Junan County, Linyi 276600, China
    2. Department of General Surgery, People's Hospital of Junan County, Linyi 276600, China
    3. Department of General Surgery, Liyuan Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430007, China
  • Received:2016-10-24 Published:2017-02-01
  • Corresponding author: Zhihui Zhao
  • About author:
    Corresponding author: Zhao Zhihui, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

张金玲, 吴超, 赵志辉. 高尔基糖蛋白73在早期原发性肝癌中的表达及意义[J]. 中华普通外科学文献(电子版), 2017, 11(01): 9-12.

Jinling1 Zhang, Chao Wu, Zhihui Zhao. Expression and significance of Golgi glycoprotein-73 in early hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2017, 11(01): 9-12.

目的

研究高尔基糖蛋白73（GP73）在早期肝癌、慢性乙型肝炎和健康者血液及肝组织中的表达情况，通过比较探讨GP73在早期肝癌中的表达及意义。

方法

采用酶联免疫反应双抗体夹心（ELISA）法检测30例成年健康者（正常组）、30例慢性乙型肝炎患者（肝炎组）及50例早期肝细胞癌（肝癌组）患者血清中GP73的质量浓度，免疫组织化学法检测20例正常肝脏、30例慢性乙型肝炎及30例早期HCC组织中GP73蛋白的表达情况。

结果

(1)肝癌组患者血清中GP73蛋白的质量浓度为（143.01±38.09）μg/L，显著高于正常组的（66.01±25.45）μg/L及肝炎组的（89.78±26.98）μg/L，且GP73蛋白在正常组、肝炎组及肝癌组血清中的质量浓度依次升高（均P<0.01）；(2) GP73蛋白在肝癌组标本中的蛋白表达分别高于肝炎组及正常组，阳性率分别为83.33%、56.67%和15.00% （χ2=5.08、22.74），肝炎组又高于正常组（χ2=8.68），差异均有统计学意义（P<0.05）。

结论

GP73蛋白在早期HCC中呈明显高表达，早期HCC患者血清中GP73蛋白的质量浓度明显高于慢性乙型肝炎及健康者；同时GP73蛋白在慢性乙型肝炎患者血清中的质量浓度亦高于健康者，提示GP73表达的升高可能与慢性HBV感染有关，可能参与了HCC的早期发生、发展。

关键词: 癌，肝细胞, 糖蛋白类, 肝炎，乙型，慢性, 高尔基糖蛋白73, 免疫组织化学
Objective

To compare the expression of Golgi glycoprotein-73 (GP73) in blood serum and tissues of early hepatocellular carcinoma (HCC), chronic hepatitis B (HBV) and healthy adults, and discuss the significance of GP73 in early HCC.

Methods

Enzyme-linked immunosorbent assay (ELISA) method was used to detect the concentration of GP73 in serum of 30 healthy adults (normal group), 30 cases with HBV (hepatitis group) and 50 cases with early HCC (cancer group). Immunohistochemical method was used to detect the tissue expression of GP73 in 20 cases of normal liver, 30 cases with chronic HBV and 30 cases with early HCC.

Results

(1) The serum concentration of GP73 in patients with early HCC was (143.01±38.09) μg/L, significantly higher than normal group (66.01±25.45) μg/L and hepatitis group (89.78±26.98) μg/L. And the concentration of GP73 increased gradually in normal, hepatitis and cancer groups (all P<0.01). (2) The expression of GP73 in early HCC tissues was higher than that in hepatitis and normal groups, the positive rates were 83.33%, 56.67% and 15.00%, respectively ( χ2=5.08, 22.74). And the positive rate of hepatitis group was higher than normal group, the difference was statistically significant ( χ2=8.68, P<0.05).

Conclusions

GP73 shows high expression in the early HCC, and GP73 in serum of HCC is significantly higher than that of chronic HBV patients and healthy adults. Meanwhile, the concentration of GP73 in serum of patients with chronic HBV is higher than that of healthy adults, suggesting that the increased expression of GP73 may be related with chronic HBV infection, and the early occurrence and development of HCC may be involved in GP73.

Key words: Carcinoma, hepatocellular, Glycoproteins, Hepatitis B, Chronic, Golgi glycoprotein-73, Immunohistochemistry
图1 GP73在各组织标本中的免疫组织化学染色结果（×200）　A为GP73在早期肝癌组织中的阳性表达；B为肝癌中阴性表达；C为肝炎组织中GP73阳性表达；D为肝炎中阴性表达；E为正常肝脏组织中GP73阳性表达；F为正常肝脏组织中阴性表达
图2 GP73蛋白在正常组、肝炎组及肝癌组血清中的表达，质量浓度依次升高
表1 GP73在血清各组中的表达
组别 n 质量浓度（μg/L，±s）a 阳性表达率[n(%)]b
正常组 30 66.01±25.45 4（13.33）
肝炎组 30 89.78±26.98 14（46.67）
肝癌组 50 143.01±38.09 48（96.00）
统计值 3.510, 9.822, 6.704a 7.937, 46.322, 26.170b
P1, 2, 3值 <0.01, <0.01, <0.01 0.005, <0.01, <0.01
[1]
Kladney RD,Bulla GA,Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene, 2000, 249(1-2): 53-65.
[2]
张启暝,何东风,李洪义. 高尔基蛋白73在原发性肝癌诊治中的意义[J]. 现代肿瘤医学, 2015, 23(17): 2452-2455.
[3]
中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2011, 16(10): 929-946.
[4]
Pang RW,Joh JW,Johnson PJ, et al. Biology of hepatocellular carcinoma[J]. Ann Surg Oncol, 2008, 15(4): 962-971.
[5]
BERGSTRAND CG,CZAR B. Paper electrophoretic study of human fetal serum proteins with demonstration of a new protein fraction[J]. Scand J Clin Lab Invest, 1957, 9(3): 277-286.
[6]
Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data[J]. Cancer Res, 1968, 28(7): 1344-1350.
[7]
Shan SG,Gao YT,Xu YJ, et al. Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients[J]. Hepatol Res, 2013, 43(11): 1199-1210.
[8]
蔡云峰,甄作均,陈焕伟, 等. 肝癌术后肝再生状态与肝癌复发关系的初步研究[J]. 中国普通外科杂志, 2008, 17(7): 692-696.
[9]
Benzoni E,Lorenzin D,Favero A, et al. Liver resection for hepatocellular carcinoma: a multivariate analysis of factors associated with improved prognosis. The role of clinical, pathological and surgical related factors[J]. Tumori, 2007, 93(3): 264-268.
[10]
Stefaniuk P,Cianciara J,Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2010,16(4): 418-424.
[11]
Gambarin-Gelwan M,Wolf DC,Shapiro R, et al. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation[J]. Am J Gastroenterol, 2000, 95(6): 1535-1538.
[12]
Block TM,Comunale MA,Lowman M, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans[J]. Proc Natl Acad Sci U S A, 2005, 102(3): 779-784.
[13]
Mao Y,Yang H,Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693.
[14]
Yamamoto K,Imamura H,Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol, 2010, 45(12): 1272-1282.
[1] 武壮壮, 张晓娟, 史泽洪, 史瑶, 原韶玲. 超声联合乳腺X线摄影及PR、Her-2预测高级别与中低级别乳腺导管原位癌的价值[J]. 中华医学超声杂志（电子版）, 2023, 20(06): 631-635.
[2] 王兴, 张峰伟. 腹腔镜肝切除联合断面射频消融治疗伴微血管侵犯肝细胞癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 580-583.
[3] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[4] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[5] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[6] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[7] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[8] 张维志, 刘连新. 基于生物信息学分析IPO7在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 694-701.
[9] 陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[10] 叶文涛, 吴忠均, 廖锐. 癌旁组织ALOX15表达与肝癌根治性切除术后预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 708-712.
[11] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
[12] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[13] 王峰杰, 王礼光, 廖珊, 刘颖, 符荣党, 陈焕伟. 腹腔镜右半肝切除术治疗肝癌的安全性与疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 517-522.
[14] 张海涛, 贾哲, 马超, 张其坤, 武聚山, 郭庆良, 曾道炳, 栗光明, 王孟龙. 手术切除与射频消融治疗血管周围型单发小肝癌临床疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 523-527.
[15] 岳瑞雪, 孔令欣, 郝鑫, 杨进强, 韩猛, 崔国忠, 王建军, 张志生, 孔凡庭, 张维, 何文博, 李现桥, 周新平, 徐东宏, 胡崇珠. 乳腺癌HER2蛋白表达水平预测新辅助治疗疗效的真实世界研究[J]. 中华临床医师杂志(电子版), 2023, 17(07): 765-770.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号